These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 10395839)

  • 1. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus.
    Chamat S; Walsh EE; Anderson D; Osta M; Awaraji C; Pan LZ; Ochi J; Shuey S; Brams P
    J Infect Dis; 1999 Aug; 180(2):268-77. PubMed ID: 10395839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.
    Johnson S; Griego SD; Pfarr DS; Doyle ML; Woods R; Carlin D; Prince GA; Koenig S; Young JF; Dillon SB
    J Infect Dis; 1999 Jul; 180(1):35-40. PubMed ID: 10353858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus.
    Hancock GE; Smith JD; Heers KM
    J Infect Dis; 2000 May; 181(5):1768-71. PubMed ID: 10823781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The characterization and uses of monoclonal antibodies to respiratory syncytial virus.
    Stott EJ; Bew MH; Taylor G; Jebbett J; Collins AP
    Dev Biol Stand; 1984; 57():237-44. PubMed ID: 6084614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The production of monoclonal antibodies against respiratory syncytial virus and its clinical applications.
    Wu B
    Clin Lab Med; 1985 Sep; 5(3):589-613. PubMed ID: 3899483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of monoclonal antibodies specific for the R transactivator 185 of Epstein-Barr virus.
    Zhu YH; Wei YS; Li H; Liang WB; Du B; Zhang GQ; Zhang L
    J Virol Methods; 2007 Sep; 144(1-2):12-6. PubMed ID: 17532480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.
    Lounsbach GR; Bourgeois C; West WH; Robinson JW; Carter MJ; Toms GL
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2559-65. PubMed ID: 7506297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
    Crowe JE; Firestone CY; Crim R; Beeler JA; Coelingh KL; Barbas CF; Burton DR; Chanock RM; Murphy BR
    Virology; 1998 Dec; 252(2):373-5. PubMed ID: 9878616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.
    López JA; Andreu D; Carreño C; Whyte P; Taylor G; Melero JA
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2567-77. PubMed ID: 7506298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains.
    Palomo C; Cane PA; Melero JA
    J Med Virol; 2000 Apr; 60(4):468-74. PubMed ID: 10686032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
    Wu H; Pfarr DS; Tang Y; An LL; Patel NK; Watkins JD; Huse WD; Kiener PA; Young JF
    J Mol Biol; 2005 Jul; 350(1):126-44. PubMed ID: 15907931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human monoclonal antibodies to viral peptides.
    Sidorova E; Borisova T; Lyakisheva L; Rosen A
    Hum Antibodies; 1997; 8(2):65-9. PubMed ID: 9289390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.
    Orvell C; Norrby E; Mufson MA
    J Gen Virol; 1987 Dec; 68 ( Pt 12)():3125-35. PubMed ID: 2447224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.
    Taylor G; Stott EJ; Furze J; Ford J; Sopp P
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2217-23. PubMed ID: 1383403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries.
    Nguyen H; Hay J; Mazzulli T; Gallinger S; Sandhu J; Teng Y; Hozumi N
    Clin Exp Immunol; 2000 Oct; 122(1):85-93. PubMed ID: 11012623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.